Cargando…
Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author’s reply
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205823/ https://www.ncbi.nlm.nih.gov/pubmed/35292826 http://dx.doi.org/10.1007/s00134-022-06669-2 |
| _version_ | 1784729210639613952 |
|---|---|
| author | Hagel, Stefan Pletz, Mathias W. Lehmann, Thomas |
| author_facet | Hagel, Stefan Pletz, Mathias W. Lehmann, Thomas |
| author_sort | Hagel, Stefan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9205823 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92058232022-06-19 Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author’s reply Hagel, Stefan Pletz, Mathias W. Lehmann, Thomas Intensive Care Med Correspondence Springer Berlin Heidelberg 2022-03-15 2022 /pmc/articles/PMC9205823/ /pubmed/35292826 http://dx.doi.org/10.1007/s00134-022-06669-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correspondence Hagel, Stefan Pletz, Mathias W. Lehmann, Thomas Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author’s reply |
| title | Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author’s reply |
| title_full | Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author’s reply |
| title_fullStr | Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author’s reply |
| title_full_unstemmed | Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author’s reply |
| title_short | Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author’s reply |
| title_sort | concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. author’s reply |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205823/ https://www.ncbi.nlm.nih.gov/pubmed/35292826 http://dx.doi.org/10.1007/s00134-022-06669-2 |
| work_keys_str_mv | AT hagelstefan concernsaboutstudydesignandsuggestionofadditionalanalysisoftherapeuticdrugmonitoringguidedpiperacillintazobactamtherapyforpatientswithsepsisauthorsreply AT pletzmathiasw concernsaboutstudydesignandsuggestionofadditionalanalysisoftherapeuticdrugmonitoringguidedpiperacillintazobactamtherapyforpatientswithsepsisauthorsreply AT lehmannthomas concernsaboutstudydesignandsuggestionofadditionalanalysisoftherapeuticdrugmonitoringguidedpiperacillintazobactamtherapyforpatientswithsepsisauthorsreply |